2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Zarnie Lwin, MBBS, FRACP, discusses the results of the LEAP-005 trial in advanced solid tumors.
Zarnie Lwin, MBBS, FRACP, associate professor, senior staff specialist, medical oncologist, Cancer Care Services, Royal Brisbane and Women’s Hospital, University of Queensland, Australia, discusses the results of the LEAP-005 trial in advanced solid tumors.
In the phase 2 trial, investigators evaluated the combination of lenvatinib (Lenvima) plus pembrolizumab (Keytruda) in patients with previously treated advanced solid tumors.
During the 2020 ESMO Virtual Congress, interim findings revealed that the objective response rates for the 6 evaluated cohorts were 29% in triple-negative breast cancer, 32% in ovarian cancer, 9.7% in gastric cancer, 21.9% in colorectal cancer, 9.7% in biliary tract cancer, and 16.1% in glioblastoma, says Lwin.
Additionally, the safety signals observed with the combination were consistent with previously reported data, Lwin adds.
The trial is expanding to include 100 patients per cohort, as it has met all prespecified efficacy criteria for cohort expansion, concludes Lwin.